Rivaroxaban
Oral Factor Xa inhibitor — FDA approved 2011. Conceptual descendant of antistasin/leech FXa research.
Mechanistic Evidence Box
Studied off-label- Page type
- Compound profile
- Evidence type
- Oral Factor Xa inhibitor — FDA approved 2011. Conceptual descendant of antistasin/leech FXa research.
- Evidence level
- FDA-cleared regulatory context
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
Rivaroxaban is a chemically synthesized small-molecule Factor Xa inhibitor; it shares only the molecular target with leech antistasin and is not structurally derived from it. Its RCT evidence base (ROCKET AF) applies only to the drug, not to whole medicinal-leech therapy.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Tier A — FDA-approved derivative
- Molecular weight
- 435.88 Da
- Source species
- Synthetic
- Discovered
- 2008 · Bayer / Johnson & Johnson
- PubChem CID
- 6433119
- Derived FDA-approved drug
- Xarelto (FDA approved July 2011)
Biological Targets
- → Factor Xa
Key Citations
- Patel MR et al. (ROCKET AF) (2011), N Engl J Med · PMID 21830957
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.